Companies
AbbVie
US immunology powerhouse — Humira (world's top-selling biologic 2012–2023) and Skyrizi/Rinvoq driving next-generation antibody manufacturing scale-up.
- Country
- United States
- Revenue
- $56.3B
- Employees
- ~50,000 emp
FDA GMP
GMP EU
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $100 billion committed to U.S. R&D and manufacturing capital investments over a decade; $2.2 billion in U.S. manufacturing investments announced since August 2025 | news.abbvie.com · abbvie.com · prnewswire.com |
| Capacity | Expanding domestic biologics, API, and small volume parenteral (SVP) drug product manufacturing capacity through multiple new facility investments in Illinois, North Carolina, Massachusetts, and Arizona | news.abbvie.com · abbvie.com · prnewswire.com |
| Certification | 100% of device-manufacturing sites are ISO 13485 certified; sites also pursue ISO 14001, ISO 45001, and ISO 50001 certifications | abbvie.com |
| Regulatory approval | Multiple ongoing FDA and EMA approvals for products like Skyrizi, Rinvoq, Vraylar, Ubrelvy, Qulipta, and Vyalev; recent approvals include Parkinson's disease therapy and c-Met overexpressing NSCLC treatment | investors.abbvie.com · fiercepharma.com · syneticx.com |
| Production site | Manufacturing sites in the U.S. (including Illinois, North Carolina, Arizona, Massachusetts) and internationally (Germany, Ireland, Italy, France, Puerto Rico, Costa Rica, Singapore) | news.abbvie.com · abbvie.com · abbviecontractmfg.com · pharmamanufacturing.com · prnewswire.com |
| Headcount | Approximately 57,000 global employees; approximately 29,000 employees in the U.S., including 6,000+ at U.S. manufacturing campuses | investors.abbvie.com · news.abbvie.com · abbvie.com · prnewswire.com |
| Revenue | $61.1 billion in total sales in 2025; total revenue of $16.99 billion for Q2 2026 | pulse2.com · fiercepharma.com |
Independent sources: fiercepharma.com · pharmamanufacturing.com · prnewswire.com · pulse2.com · syneticx.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biologics | therapeutics-platforms | Low | → |
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
| Bispecific & multispecific antibodies | therapeutics-platforms | Low | → |
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.